Malignant Hyperthermia: Difference between revisions

From PedsAnesthesiaNet
Jump to navigation Jump to search
No edit summary
No edit summary
Line 28: Line 28:


Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing.  Anesthesiology. 2022 Jun 1;136(6):940-953. PMID: 35285867
Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing.  Anesthesiology. 2022 Jun 1;136(6):940-953. PMID: 35285867
[https://www.bjanaesthesia.org/article/S0007-0912(22)00496-2/fulltext Functional analysis of RYR1 variants in patients with confirmed susceptibility to malignant hyperthermia]

Revision as of 18:15, 14 October 2022

This is a Stub Notice. This page has not been completed. You can work on this page by signing in and going to the Edit tab. Thanks for helping to make PedsAnesthesia.Net Wiki useful.

Go to the Main Page to see the Topic Outline.

Go to the Generalized Suggested Outline for information on case-specific details for each page.

Go to the Test Page for examples on how to use references in the page.


https://link.springer.com/chapter/10.1007/978-4-431-68346-9_1

See also http://www.mhaus.org

Malignant hyperthermia 2020 Guideline from the Association of Anaesthetists P. M. Hopkins T. Girard S. Dalay B. Jenkins A. Thacker M. Patteril E. McGrady First published: 05 January 2021 https://doi.org/10.1111/anae.15317

http://malignanthyperthermia.org.au/resource-kit/


https://twitter.com/hypoxicchicken/status/1232963055467712514?s=21

Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice

Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing. Anesthesiology. 2022 Jun 1;136(6):940-953. PMID: 35285867

Functional analysis of RYR1 variants in patients with confirmed susceptibility to malignant hyperthermia